BioNTech
NEWS
In documents prepared for the meeting, the vaccine demonstrated 90.7% effectiveness for the children in this age group.
BioNTech plans to increase its manufacturing capacity in Africa over time through the supplementation of new manufacturing lines and construction of additional manufacturing sites.
If the panel votes in favor of the vaccine for children, it will move to the U.S. CDC. If both agencies support the data, children this age would be likely to receive their first shots in early November.
Some fear potential side effects, and more just aren’t sure about the quality and risks associated with a vaccine developed in an unprecedented nine months.
The U.S. Food and Drug Administration posted analyses of the Pfizer-BioNTech COVID-19 vaccine in children ages 5 to 11 years old ahead of Tuesday’s vaccines advisory committee meeting.
The U.S. FDA has a busy period at the end of October heading into the first week of November.
It was yet another busy week for clinical trial news. Here’s a look.
Atreca announced it is licensing its preclinical monoclonal antibody for the prevention of malaria to the Gates Medical Research Institute (MRI) for development.
The CDC supported the FDA’s approval of mixing and matching vaccines, where eligible populations can take a booster shot from another brand different from their initial series.
JOBS
IN THE PRESS